“Advanced Concepts in Cellular Immune Control of Cytomegalovirus”, Deutsche Forschungsgemeinschaft (DFG), coordinator: Lars Dölken, 16 independent researchers including Stipan Jonjić and Vanda Juranić Lisnić, 2019 – 2025
“New Cytomegaloviral vaccine vector concepts”, Helmholtz European Partnering, coordinator: Luka Cicin-Sain (Helmholtz Center for Infection Research); 6 partners including Stipan Jonjic (University of Rijeka, Faculty of Medicine), 2019 – 2024
“Inflammation and hearing loss following congenital CMV infection” (resubmission), National Institutes of Health (NIH) R01, coordinator: William J Britt, (University of Alabama at Birmingham, USA); 2 partners including University of Rijeka, Faculty of Medicine, 2017 – 2022, no-cost extension
“Centre of Excellence for Research in Viral Immunology and the Development of New Vaccines (CERVirVac)”, European Regional Development Fund, Ministry of Science and Education of the Republic of Croatia, coordinator Stipan Jonjic (University of Rijeka, Faculty of Medicine), partners: Center for Research and Knowledge Transfer in Biotechnology of the University of Zagreb and The University Hospital for Infectious Diseases (Zagreb), 2014 – 2024
“Deletion mutants of cytomegalovirus” (006204), Ministry of science and technology of the Republic of Croatia, 1996
“Perinatal cytomegalovirus infection” (006205), Ministry of science and technology of the Republic of Croatia, 1996
“CMV infection and immunosuppression” (1.08.05.04.06), Ministry of science and technology of the Republic of Croatia, 1987 – 1990
“Surveillance of cytomegalovirus infections” (3-01-169), Ministry of science and technology of the Republic of Croatia, 1991 – 1996
“Immunosurveillance of cytomegalovirus latency” (JF 190), US – Croatian Science Technology Program, 1995 – 1997
“Regulation of NK-cell receptors by herpes viruses” (0062004), Ministry of science and technology of the Republic of Croatia, 2002
“Antiviral Antibodies and CNS Infection with CMV – Fogarty International Research Collaboration Award (FIRCA)”, National Institutes of Health, Bethesda, USA (together with Dr. William J. Britt, University of Alabama, Birmingham, USA), co-PI Stipan Jonjic, 1999 – 2002
“CNS Maldevelopment and Perinatal Infection” (1 R01 HD044721-01), National Institutes of Health, Bethesda, USA (together with Dr. William J. Britt, University of Alabama, Birmingham, USA), co-PI Stipan Jonjic, 2003 – 2008
“Center for Monoclonal Antibody Production (JEZGRA 17)”, Ministry of science and technology of the Republic of Croatia, PI Stipan Jonjic, 2003 – 2007
“Establishment of high-throughput monoclonal antibody production and hybridoma bank” (FP6-2002-INCO-WBC/SSA-3), PI Stipan Jonjic, 2006 – 2008
“Natural Killer Cell-Mediated Anti-Viral and Anti Tumor Defense and Therapy: Integrated research training in molecular medicine, bioinformatics and issues of biotech patents and SME business” (EU FP6), Marie Curie Research Training Networks Coordinator: E. Hofer, Medical University of Vienna, partner Stipan Jonjic, 2006 – 2009
“Conference of the society for natural immunity” (1R13AI089016-01), National Institutes of Health (NIH) USA, co-PI Stipan Jonjic, 2009
“Transcriptomic Approach to Viral Disease Research”, Unity Through Knowledge Fund (UKF), Grant Joanne Trgovcich (The Ohio State University, Columbus OH, USA) and Stipan Jonjic (Center for Proteomics – Faculty of Medicine, University of Rijeka), 2007 – 2010
“The function of the NK killer receptor NKp46 in CMV and Influenza infection”, Croatia – Israel joint research program, PI Stipan Jonjic, 2009 – 2011
“The development of a model for immunotherapy of viral infections by using recombinant proteins which connect the innate and specific immune respons”, The National Foundation for Science, Higher Education and Technological Development of the Republic of Croatia, PI Stipan Jonjic, 2008-2011
“The Center for Antibody Production Rijeka: Upgrading the Central Research and Service Infrastructure for the South Eastern Region of Europe” (EU FP7-REGPOT- 2008- 1), PI Stipan Jonjic, 2009 – 2012
“Upgrading the capacities for research in translational medicine at the Faculty of Medicine University of Rijeka (TransMedRi)” (256686), (EU FP7-REGPOT- 2010-5), S. Jonjic, together with colleagues from the Faculty of Medicine prepared the project proposal. This is an institutional grant coordinated by the Vice-Dean for Science of the Faculty of Medicine, Bojan Polic. The project aims to strengthen the research potential of the Faculty of Medicine for translational research in biomedicine, particularly in the fields of infectious diseases and cancer. 2010 – 2013
“Molecular mechanisms of immune evasion by cytomegalovirus” (062-0621261-1263), Ministry of Science, Education and Sports, PI Stipan Jonjic, 2007 – 2011
“The role of cystatins in immune response to viruses” (001.10-1264), Croatia-Slovenia cooperation in science and technology, Ministry of Science, Education and Sports, co-PI Stipan Jonjic, 2012 – 2013
“Viral evasion of NK cells” (1RO1AI083201-01), National Institutes of Health (NIH) USA, PI Stipan Jonjic, 2009 – 2013
“New strong CMV-promoter for protein and RNA production” Business Inovation Center of Croatia BICRO, PI Stipan Jonjic, 2012 – 2013
“MCMV Infection of the Developing CNS: Neuroinvasion and immune Control” (1R01NS065845-01), National Institutes of Health, Bethesda, USA (together with Dr. William J. Britt, University of Alabama, Birmingham, USA), co-PI Stipan Jonjic, 2010 – 2015
“Becoming entrepreneurial: knowledge transfer from the University of Rijeka Faculty of Medicine to the biotechnology business sector”, Instrument for Pre-accession Assistance – IPA, PI Stipan Jonjic, partner PI Martin Messerle, 2013 – 2015
“Immunosurveillance mechanisms of herpesvirus infection and development of new virus vaccines and vaccine vectors” (Uniri projects/516), University of Rijeka, 2013 – 2014
“Congenital CMV and CNS infection mechanisms of protective immunity” (1RO1AI089956-01A1), National Institutes of Health, Bethesda, USA (together with Dr. William J. Britt, University of Alabama, Birmingham, USA), co-PI Stipan Jonjic, 2011 – 2017
“Viral Strategies of Immune Evasion (VISTRIE)”, partners: Luka Cicin-Sain, Melanie Brinkmann (Helmholtz Centre for Infection Research, Braunschweig, Germany), Martin Messerle (Medical School Hannover, Germany), Ulrich Kalinke (TWINCORE Centre for Experimental and Clinical Infection Research, Hannover, Germany), Hartmut Hengel, Anne Halenius (University Hospital Düsseldorf, Germany), Stipan Jonjic, 2011 – 2016
“Platform for trans-Academic Cooperation in Innovation (PACINNO)” IPA Adriatic CBC Strategic project proposals, coordinator: University of Trieste; 7 partners from the Adriatic region (Stipan Jonjic), 2013-2016
“The integrated anti-HCMV/anti-GBM vaccine”, HAMAG-BICRO Proof of Concept Programme (PoC) 6, coordinator: Hrvoje Simic, partner Stipan Jonjic, 2016
“Strengthening adaptive immunity via innate immunity: enhancing the CD8 T cell response by using the NKG2D ligand expressed in a herpesvirus vector” (StAdvInn) (EU FP7 ERC-2012-AdG_322693-Ideas), PI Stipan Jonjic, 2013 – 2018
“Methods for high-throughput glycoproteomic analysis (HTP-GlycoMet)” (324400), FP7 program Marie Curie Actions – Industry-Academia Partnerships and Pathways, coordinator: University of Rijeka, partners: Stipan Jonjic (Faculty of Medicine Rijeka, Croatia), Genos (Zagreb, Croatia), Bia Separations (Ajdovščina, Slovenia), Max Planck Society (Magdeburg, Germany), 2013 – 2017
“A training network for the rational design of the next generation of well-defined glycoconjugate vaccines (GLYCOVAX)”, coordinator: NOVARTIS vaccines and diagnostics (11 partners, including Faculty of Medicine Rijeka, Stipan Jonjic); HORIZON 2020, Marie Sklodowska-Curie Innovative Training Networks, 2015 – 2019
“Augmenting and broadening T-cell responses to glioblastoma – therapeutic vaccine platform based on HCMV expressing NKG2D ligands (GLIOVACC)”, European Commission – European Research Council, Horizon 2020 / ERC-Proof of Concept – ERC-2018-PoC, coordinator: Stipan Jonjic, 2018 – 2019
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Tehničko skladištenje ili pristup su neophodni za legitimnu svrhu čuvanja podešavanja koje ne traži pretplatnik ili korisnik.
The technical storage or access that is used exclusively for statistical purposes.Tehničko skladište ili pristup koji se koristi isključivo u anonimne statističke svrhe. Bez sudskog naloga, dobrovoljne suglasnosti od strane vašeg dobavljača internet usluge ili dodatnih zapisa treće strane, informacije sačuvane ili preuzete samo za ovu svrhu obično se ne mogu koristiti za vašu identifikaciju.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.